# Placeholder Target Arm Sequences
#
# These are well-characterized therapeutic antibodies to use as the
# tumor-targeting arm in bispecific constructs for testing/demonstration.
#
# The CD3 binder designed in this project will be paired with one of
# these target arms. Replace with your actual target antibody.

# Trastuzumab (Herceptin) - Anti-HER2
# Most common placeholder for bispecific development
trastuzumab:
  name: Trastuzumab (Herceptin)
  target: HER2 (ERBB2)
  indication: HER2+ breast cancer, gastric cancer
  approval: FDA 1998
  isotype: IgG1

  vh_sequence: >-
    EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSV
    KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS

  vl_sequence: >-
    DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSG
    SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK

  cdrs:
    cdr_h1: DTYIH
    cdr_h2: RIYPTNGYTRYADSV
    cdr_h3: WGGDGFYAMDY
    cdr_l1: RASQDVNTAVA
    cdr_l2: SASFLYS
    cdr_l3: QQHYTTPPT

  binding:
    target_epitope: Domain IV of HER2 ECD
    kd_nm: 5
    cross_reactivity:
      human: true
      cynomolgus: true
      mouse: false

  notes: >-
    Standard choice for bispecific development. Well-characterized,
    cross-reacts with cynomolgus HER2 for preclinical studies.

# Rituximab - Anti-CD20
rituximab:
  name: Rituximab (Rituxan)
  target: CD20
  indication: B-cell lymphomas, CLL, autoimmune diseases
  approval: FDA 1997
  isotype: IgG1

  vh_sequence: >-
    QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKF
    KGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSS

  vl_sequence: >-
    QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGS
    GSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK

  binding:
    target_epitope: CD20 extracellular loop
    kd_nm: 8
    cross_reactivity:
      human: true
      cynomolgus: true
      mouse: false

  notes: >-
    Good for B-cell targeting bispecifics. Blinatumomab (CD19xCD3)
    is the approved BiTE in this space.

# Cetuximab - Anti-EGFR
cetuximab:
  name: Cetuximab (Erbitux)
  target: EGFR (HER1)
  indication: Colorectal cancer, head and neck cancer
  approval: FDA 2004
  isotype: IgG1

  vh_sequence: >-
    QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFT
    SRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA

  vl_sequence: >-
    DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG
    SGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK

  binding:
    target_epitope: EGFR domain III
    kd_nm: 0.4

  notes: >-
    Very high affinity. Good for solid tumor bispecifics.
    Chimeric (mouse/human), so less ideal as template.

# Configuration for bispecific assembly
default_target:
  name: trastuzumab
  rationale: >-
    Well-characterized, FDA-approved, cross-reacts with cynomolgus,
    humanized (good template for human frameworks).

# How to swap target
usage:
  description: >-
    To use a different target arm, modify config.yaml:

    formatting:
      tumor_target: rituximab  # or your custom target

  custom_target: >-
    To add a custom target, create a new YAML file in this directory
    following the trastuzumab format, then reference it in config.yaml.
